Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium
Lists
Only you see this
Abstract
Antiplatelet response to clopidogrel shows wide variation, and poor response is correlated with adverse clinical outcomes. CYP2C19 loss-of-function alleles play an important role in this response, but account for only a small proportion of variability in response to clopidogrel. An aim of the International Clopidogrel Pharmacogenomics Consortium (ICPC) is to identify other genetic determinants of clopidogrel pharmacodynamics and clinical response. A genomewide association study (GWAS) was performed using DNA from 2,750 European ancestry individuals, using adenosine diphosphate-induced platelet reactivity and major cardiovascular and cerebrovascular events as outcome parameters. GWAS for platelet reactivity revealed a strong signal for CYP2C19*2 (P value = 1.67e-33). After correction for CYP2C19*2 no other single-nucleotide polymorphism reached genomewide significance. GWAS for a combined clinical end point of cardiovascular death, myocardial infarction, or stroke (5.0% event rate), or a combined end point of cardiovascular death or myocardial infarction (4.7% event rate) showed no significant results, although in coronary artery disease, percutaneous coronary intervention, and acute coronary syndrome subgroups, mutations in SCOS5P1, CDC42BPA, and CTRAC1 showed genomewide significance (lowest P values: 1.07e-09, 4.53e-08, and 2.60e-10, respectively). CYP2C19*2 is the strongest genetic determinant of on-clopidogrel platelet reactivity. We identified three novel associations in clinical outcome subgroups, suggestive for each of these outcomes.
BibTeX
@inproceedings{verma2020genomewide,
author = {Shefali S. Verma and Thomas O. Bergmeijer and Li Gong and Jean‐Luc Reny and Joshua P. Lewis and Braxton D. Mitchell and Dimitrios Alexopoulos and Dániel Aradi and Russ B. Altman and Kevin P. Bliden and Yuki Bradford and Gianluca Campo and Kiyuk Chang and John H. Cleator and Jean‐Pierre Déry and Nadia Dridi and Israel Fernández‐Cadenas and Pierre Fontana and Meinrad Gawaz and Tobias Geisler and Gian Franco Gensini and Betti Giusti and Paul A. Gurbel and Willibald Hochholzer and Lene Holmvang and Eun Young Kim and Ho‐Sook Kim and Rossella Marcucci and Joan Montaner and Joshua Backman and Ruth E. Pakyz and Dan M. Roden and Elke Schaeffeler and Matthias Schwab and Jae Gook Shin and Jolanta M. Siller‐Matula and Jurriën M. ten Berg and Dietmar Trenk and Marco Valgimigli and John R. Wallace and Ming‐Shien Wen and Michiaki Kubo and Ming Ta Michael Lee and Ryan Whaley and Stefan Winter and Teri E. Klein and Alan R. Shuldiner and Marylyn D. Ritchie and for the ICPC Investigators},
title = {{Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium}},
booktitle = {Clinical},
year = {2020},
doi = {10.1002/cpt.1911},
}Loading related content...